Analysts Set Bio-Rad Laboratories, Inc. (NYSE:BIO) PT at $327.40

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $327.40.

Several equities research analysts recently issued reports on the company. Citigroup decreased their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. StockNews.com downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. UBS Group decreased their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Royal Bank of Canada cut their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several institutional investors have recently added to or reduced their stakes in the business. CenterBook Partners LP boosted its holdings in Bio-Rad Laboratories by 125.5% in the 1st quarter. CenterBook Partners LP now owns 26,654 shares of the medical research company's stock worth $6,492,000 after buying an additional 14,835 shares during the period. Headlands Technologies LLC lifted its position in shares of Bio-Rad Laboratories by 64.1% during the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock worth $87,000 after acquiring an additional 139 shares in the last quarter. Ontario Teachers Pension Plan Board boosted its stake in Bio-Rad Laboratories by 8.8% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 2,217 shares of the medical research company's stock worth $540,000 after purchasing an additional 179 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Bio-Rad Laboratories by 5.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 203,180 shares of the medical research company's stock valued at $49,487,000 after buying an additional 11,313 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. bought a new stake in shares of Bio-Rad Laboratories during the first quarter valued at about $461,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 0.9 %

NYSE:BIO traded down $2.20 on Thursday, hitting $238.82. The stock had a trading volume of 244,720 shares, compared to its average volume of 319,090. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories has a 52 week low of $215.38 and a 52 week high of $387.99. The business's fifty day moving average is $244.34 and its 200 day moving average is $301.54. The company has a market cap of $6.69 billion, a PE ratio of -3.67 and a beta of 1.00.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. The firm had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The business's quarterly revenue was down 4.2% compared to the same quarter last year. During the same period last year, the firm earned $2.30 earnings per share. On average, equities research analysts expect that Bio-Rad Laboratories will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.